A clinical comparison of an endothelin receptor antagonist and phosphodiesterase-5 inhibitors for treating digital ulcers of systemic sclerosis
Abstract
OBJECTIVES
To assess the efficacy of an endothelin receptor antagonist (ERA) and phosphodiesterase-5 inhibitors (PDE5i) for treating systemic sclerosis (SSc)-related digital ulcers (DUs).
METHODS
This prospective, multicenter, observational cohort study recruited patients with active SSc-related DUs from 13 medical centers in South Korea. The primary outcome was time to cardinal ulcer (CU) healing. Secondary outcomes included time to new DU occurrence. Patients were followed up 4, 8, 12, and 24 weeks after treatment initiation.
RESULTS
Sixty-three patients were analyzed. Their mean age was 49.9 ± 11.4 years and 49 were female. Twenty-eight had limited SSc. Forty-nine patients received the ERA, 11 patients received a PDE5i (nine sildenafil, one udenafil, and one tadalafil), and three patients received other medication. The hazard ratio (HR) for time to CU healing in the ERA group versus the PDE5i group was 0.75 (95% CI: 0.35-1.64, p = 0.47) in an unadjusted model and 0.80 (95% CI: 0.36-1.78, p = 0.59) in a model adjusted for age, sex, use of calcium channel blockers (CCBs), total DU numbers, and initial CU area. The HR for new DU development in the ERA group versus the PDE5i group was 0.39 (95% CI: 0.16-0.93, p = 0.03) in an unadjusted model and 0.32 (95% CI: 0.13-0.81, p = 0.02) in an adjusted model. No patients receiving CCBs developed new DUs at 24 weeks.
CONCLUSION
Time to CU healing is comparable for ERA and PDE5i. An ERA is more effective in reducing new DU occurrence…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 11 participants or records.
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.